HSBC Upgrades Gilead Sciences to Buy, Raises Price Target to $155

Benzinga Newsdesk www.benzinga.com Positive 84.2%

Neg 0% Neu 0% Pos 84.2%

HSBC analyst Morten Herholdt upgrades Gilead Sciences (NASDAQ:GILD) from Hold to Buy and raises the price target from $133 to $155.